Nipah Vaccine Achieves Milestone with Positive First Human Trial Results

A Nipah virus vaccine candidate has successfully completed its first human trial, demonstrating safety and generating a strong immune response. This marks a significant step towards developing a much-needed defense against the deadly virus, particularly for countries like India.

• First human trial of a Nipah vaccine found safe and immunogenic.
• Study, published in Lancet, highlights a significant milestone in vaccine development.
• Two doses of the vaccine proved more effective in stimulating immune response.
• Nipah virus is a WHO priority pathogen with high fatality rates.
• No approved Nipah vaccine currently exists globally.
• India, Bangladesh, and Southeast Asia face recurring Nipah outbreaks.

Read the full story on Quick Digest.